Moreover, in vivo experiments will improve our understanding of the HOPS–p53 interaction, clarifying whether the reduction in the HOPS-mediated p53 response observed in hemizygosity might lead to a different susceptibility to cancer. The gene discussed is TP53; the disease is cancer.